Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.66 |
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 11/20 | 0.64 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19267603 | 0.84 | RAB9A (0.72) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL14825155 | 0.84 | RAB9A (0.75) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL3140270 | 0.82 | SMN1; SMN2 (0.65) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL24415616 | 0.81 | KMT2A (0.61) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL19625304 | 0.81 | KMT2A (0.61) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL7125440 | 0.80 | SREBF2 (0.58) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL18114095 | 0.80 | MEN1 (0.74) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL3134349 | 0.79 | ALDH1A1 (0.73) | KMT2AGAAMEN1MAPTALDH1A1 | |
| SCHEMBL16607135 | 0.79 | ALDH1A1 (0.76) | KMT2AGAAGFERMEN1MAPT | |
| SCHEMBL27400125 | 0.79 | TP53 (0.54) | KMT2AGAAGFERMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3626240-A1 | PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP | StemSynergy Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626240-A1 | PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP | StemSynergy Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| CN-1437588-A | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | BIOVITRUM AB (SE) | 2003-08-20 | — | — | CN | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1283832-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001090092-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
| US-4207233-A | Azo dyes containing a thiazole component | BASF AKTIENGESELLSCHAFT (DE) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | KMT2A 3839/4885GAA 2252/4885GFER 4655/4885 |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | KMT2A 3839/4885GAA 2252/4885GFER 4655/4885 |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | KMT2A 3839/4885GAA 2252/4885GFER 4655/4885 |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | KMT2A 3304/4885GAA 373/4885GFER 2781/4885 |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | WNT3A, WNT1, WNT3 | KMT2A 3839/4885GAA 2252/4885GFER 4655/4885 |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | KMT2A 3839/4885GAA 2252/4885GFER 4655/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | KMT2A 790/4885GAA 3778/4885GFER 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.